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SUMOylation regulates AKT1 activity
CF de la Cruz-Herrera1, M Campagna1, V Lang2, J del Carmen González-Santamaría1, L Marcos-Villar1, MS Rodríguez2,
A Vidal3, M Collado4 and C Rivas1,5
Serine threonine kinase AKT has a central role in the cell, controlling survival, proliferation, metabolism and angiogenesis.
Deregulation of its activity underlies a wide range of pathological situations, including cancer. Here we show that AKT is post-
translationally modified by the small ubiquitin-like modifier (SUMO) protein. Interestingly, neither SUMO conjugation nor activation
of SUMOylated AKT is regulated by the classical AKT targeting to the cell membrane or by the phosphoinositide 3-kinase pathway.
We demonstrate that SUMO induces the activation of AKT, whereas, conversely, down-modulation of the SUMO machinery
diminishes AKT activation and cell proliferation. Furthermore, an AKT SUMOylation mutant shows reduced activation, and
decreased anti-apoptotic and pro-tumoral activities in comparison with the wild-type protein. These results identify SUMO as
a novel key regulator of AKT phosphorylation and activity.
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INTRODUCTION
Increased activity of AKT also known as, Protein Kinase B (PKB) is
one of the most common alterations observed in human cancer.1
However, this hyperactivation of AKT is frequently not the result of
mutation in the gene encoding this kinase. AKT has an amino-
terminal pleckstrin homology (PH) domain, which is essential for
binding phosphatidylinositol (3,4,5)-trisphosphate, a lipid second
messenger produced by phosphoinositide 3-kinase (PI3K), the
upstream activator of the signaling cascade. The PH domain is
followed by an α-helical linker and a C-terminal kinase domain,
critically controlled by phosphorylation.2 In unstimulated cells,
AKT localizes to the cytosol, where it is maintained in an inactive
conformation through the interaction between its PH and kinase
domains.3 In the presence of proliferative signals, PI3K is activated
and generates phosphatidylinositol (3,4,5)-trisphosphate that
serves for the docking of AKT to the plasma membrane through
binding to its PH domain. Membrane recruitment results in a
conformational change that separates the PH and the kinase
domains, unmasking two regulatory residues in AKT, threonine
308 and serine 473. Phosphorylation of these two residues is
required for maximal activation of the kinase.4
The increased activity of AKT in cancer cells provides survival
signals, support higher proliferative rates, alters metabolism and
promotes cell migration. Tumor cells frequently depend on this
high AKT activity for survival and therefore, understanding AKT
activation and its regulation are important for the creation of
better therapies to treat cancer.
SUMOylation is an important post-translational modification
that has a pivotal role in a myriad of biological functions, including
DNA damage response, cell growth, innate immune response,
etc.5 SUMOylation involves the covalent attachment of a member
of the small ubiquitin-like modifier (SUMO) family of proteins to
lysine residues in specific target proteins via an enzymatic cascade
analogous to, but distinct from, the ubiquitylation pathway.6 In
this report, we show that AKT can conjugate to SUMO in vitro and
in vivo. We have identified the lysine residues in AKT that work as
main SUMO acceptors. We found that SUMOylation of AKT is not
affected by its targeting to the cell membrane nor responds to the
PI3K pathway, but it can be stimulated by cellular stress and it is
negatively modulated by the promyelocytic leukemia (PML) tumor
suppressor protein. Furthermore, we show that SUMO favors the
activation of the protein, whereas Ubc9 down-modulation has the
opposite effect. Finally, we demonstrate that an AKT SUMOylation
mutant presents reduced activation that leads to a diminished
anti-apoptotic activity, and a weaker oncogenic ability when
compared with the wild-type (WT) protein. In summary, here we
identify SUMO as a new crucial AKT kinase coactivator.
RESULTS
AKT1 is modified by SUMO
During the course of our previous studies on the SUMOylation of
the phosphatase and tensin homolog (PTEN),7 we noticed that
AKT could also be found SUMOylated. Therefore, we proceeded to
evaluate the putative conjugation of AKT to SUMO. In vitro
SUMOylation assays were done using in vitro translated [35S]
methionine-labeled AKT1 protein, as a substrate. We detected
AKT1 protein as a single band of the expected 60 kDa predicted
molecular weight. When the reaction was incubated with SUMO1,
SUMO2 or SUMO3, we observed higher-molecular-weight bands
of around 75–80 and 90–95 kDa (Figure 1a, left panel), indicating
that AKT1 is modified by SUMO1, SUMO2 and SUMO3 in vitro. To
further prove that the bands correspond to AKT1-SUMO
conjugates, we incubated AKT1-SUMO1 protein with the recom-
binant SUMO-specific protease SENP1. The high-molecular-weight
bands detected in the lane corresponding to AKT1-SUMO1
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Figure 1. Covalent modification of AKT1 by SUMO1, SUMO2 and SUMO3 in vitro and in vivo. (a) In vitro translated [35S]-labeled AKT1 was
subjected to in vitro SUMOylation assay in the presence of SUMO1, SUMO2 or SUMO3 (left panel). SUMO1-conjugated AKT1 protein was then
incubated with or without SENP1 as described in Materials and Methods (right panel). Proteins were resolved by SDS–polyacrylamide gel
electrophoresis (PAGE) and visualized by autoradiography. (b) AKT1 is modified by SUMO2 and SUMO3 in vivo. HEK-293 cells were co-
transfected with HA-AKT1 together with pcDNA, Ubc9 and His6-SUMO1, Ubc9 and His6-SUMO2 or Ubc9 and His6-SUMO3. Whole protein
extracts or histidine-tagged purified proteins were analyzed by western blot (WB) analysis using anti-HA antibody. (c) Modification of
transfected HA-AKT1 by SUMO1 in HEK-293 cells after heat stress (HS). HEK-293 cells were co-transfected with HA-AKT1 together with pcDNA
or Ubc9 and His6-SUMO1 and 36 h after transfection cells were heat stressed by incubation at 45 °C for 20min. Whole protein extracts or
histidine-tagged purified proteins were analyzed by western blot analysis using anti-HA antibody. U, untreated cells. (d) Modification of
endogenous AKT by SUMO2/3 in HEK-293 cells. HEK-293 cells were transfected with pcDNA or Ubc9 and His6-SUMO2. Whole protein extracts
or histidine-tagged purified proteins were analyzed by western blot analysis using anti-AKT antibody (left panel). Protein extracts from
untransfected HEK-293 cells were subjected to immunoprecipitation (IP) with anti-SUMO2/3 antibodies or with IgG control, as indicated.
Immunoprecipitated samples were run on a SDS–PAGE gel and were analyzed by western blot analysis using anti-AKT antibody (right panel).
(e) Co-immunoprecipitation of endogenous AKT with transfected SV5-Ubc9 in HEK-293 cells. Protein extracts from HEK-293 cells transfected
with SV5-Ubc9 were subjected to immunoprecipitation with anti-SV5 antibody or with IgG control, as indicated. Immunoprecipitated samples
were run on a SDS–PAGE gel and were analyzed by western blot using anti-AKT antibody.
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disappeared after incubation of the reaction with SENP1
(Figure 1a, right panel). All together, these results demonstrate
that AKT1 is SUMOylated in vitro. In addition, the presence of
several bands corresponding to AKT1-SUMO1 in the in vitro assay
indicates that SUMOylation occurs at more than one site. Then, in
order to determine whether AKT1 also conjugates to SUMO within
the cell, HEK-293 cells were co-transfected with HA-tagged AKT1
together with Ubc9 and His6-tagged SUMO1, SUMO2, SUMO3 or
pcDNA plasmids. At 48 h after transfection, His6-tagged proteins
were purified in denaturing conditions using nickel beads.
Western blot analysis of the purified extracts with anti-HA
antibody revealed bands of the expected size corresponding to
AKT1-SUMO proteins only in those cells co-transfected with His6-
SUMO2 or His6-SUMO3 (Figure 1b, left panel), indicating that AKT1
is modified by SUMO2 and SUMO3 in vivo. However, we could not
detect the expected AKT1-SUMO1 bands in those cells transfected
with His6-SUMO1 (Figure 1b, right panel), despite repeated
attempts and using different cell lines, suggesting AKT1 is not
modified by SUMO1 in vivo under these conditions. It has been
previously described that some stress conditions can induce
SUMO conjugation,8–12 therefore we decided to evaluate the
conjugation of AKT1 to SUMO1 in stressed cells. HEK-293 cells
were co-transfected with HA-AKT1 and pcDNA or His6-SUMO1 and
Ubc9, and 36 h after transfection, cells were heat stressed by
incubation at 45 °C for 20 min. Whole-cell extracts and histidine-
tagged purified proteins were then analyzed by western blot
analysis. As shown in Figure 1c, we could not detect AKT1-SUMO1
in the untreated cells, as previously observed. However, we can
see clear AKT1-SUMO1 bands in the stressed cells. These results
demonstrate that AKT1 could be conjugated to SUMO1 in vivo
under stress conditions. Furthermore, similar experiments done
with SUMO2 revealed an increase in the AKT1 conjugation to
SUMO2 under heat-shock stress (Supplementary Figure 1). To
confirm that endogenous AKT protein is modified by SUMO2, total
protein extracts and His-tagged purified proteins obtained from
HEK-293 cells transfected with His6-SUMO2 and Ubc9 were
analyzed by western blot analysis using anti-AKT antibody. Bands
of the expected size corresponding to AKT-SUMO2 protein were
detected only in the cells transfected with His6-SUMO2 (Figure 1d,
left panel), indicating that endogenous AKT protein can be
modified by SUMO2. Modification of endogenous AKT protein by
SUMO2/3 was also determined by immunoprecipitation analysis.
Endogenous SUMO2/3 protein was immunoprecipitated from
untransfected HEK-293 cells using anti-SUMO2/3 antibody and a
band with a molecular weight similar to the upper AKT-SUMO2
band was detected using anti-AKT antibody (Figure 1d, right
panel). SUMOylated proteins interact with the E2 SUMO-
conjugating enzyme Ubc9 as part of the SUMOylation process.
Thus, we decided to evaluate the putative interaction between
Ubc9 and AKT. HEK-293 cells were transfected with SV5-Ubc9
and at 48 h we analyzed the co-immunoprecipitation of both
proteins. As shown in Figure 1e, endogenous AKT co-immuno-
precipitated with Ubc9. All together, these data demonstrate
that AKT can be conjugated to SUMO1, SUMO2 and SUMO3
in vitro and in vivo.
Identification of the SUMO-modification sites in AKT1
The SUMOplot prediction system identified four putative SUMO
consensus sites (K64, K182, K189 and K276) in AKT1. We
constructed single or double AKT1 mutants in the putative lysine
residues and analyzed their capability to conjugate to SUMO
in vitro. We observed a clear reduction in SUMO2 conjugation in
single mutant proteins in which we mutated individually lysines
64, 182 or 189 (AKT1-K64R, AKT1-K182R and AKT1-K189R,
respectively) and in the double mutant in the lysine residues
182 and 189 AKT1-K182RK189R (Figure 2a). Similarly, we also
observed a clear reduction in SUMO1 conjugation to AKT1-K64R
and AKT1-K182RK189R (Supplementary Figure 2). These results
pointed to the lysine residues 64, 182 and 189 as SUMO-acceptor
sites in AKT1. To verify this information, we constructed a triple
AKT1 mutant in the lysine residues 64, 182 and 189 (AKT1-SMUT)
and then, we analyzed its capability to conjugate to SUMO in vitro
and in vivo. We observed a reduction in SUMO1 conjugation to
AKT1-SMUT in comparison with the WT protein (Supplementary
Figure 2) and we did not detect any band corresponding to AKT1-
SMUT protein conjugated to SUMO2 (Figure 2b) in vitro.
Importantly, SUMO2 modification of AKT1-SMUT was decreased
to almost undetectable levels in vivo (Figure 2c), indicating that
lysine residues 64, 182 and 189 in AKT1 are implicated in the
conjugation to SUMO.
SUMO increases the activity of AKT in vitro and in vivo
In order to evaluate the effect of SUMO conjugation on the AKT
activity, we carried out an in vitro kinase assay using unmodified or
SUMOylated recombinant AKT1 protein, and recombinant p27
protein as AKT substrate. As expected, unmodified AKT1 induced
the phosphorylation of p27 (Figure 3a), whereas a clear increase in
the levels of phosphorylated p27 was detected when we used
AKT1 that had been previously subjected to an in vitro SUMOyla-
tion reaction in the presence of SUMO2 (Figure 3a) or SUMO1
(Supplementary Figure 3). These results indicated that SUMO
increased the kinase activity of AKT1 in vitro. To determine
whether SUMOylation regulates the activity of AKT in vivo, we
evaluated the phosphorylation ratio of AKT-WT versus AKT-SMUT
in cells. MCF-7 cells were transfected with pcDNA, HA-AKT1-WT or
the SUMOylation mutant HA-AKT1-SMUT, and 24 h after
transfection, cells were serum deprived for 24 h and stimulated
or not with insulin. Transfected AKT1 protein was immunopreci-
pitated using anti-HA antibody and then western blot analysis
using anti-phospho-AKT antibody was carried out. The ratio of
phosphorylated/unphosphorylated SUMOylation mutant AKT1
protein (p-AKT1-SMUT/AKT1-SMUT) was clearly lower than that
of the WT AKT1 protein (Figure 3b). In addition, although insulin
treatment induced an increase in the p-AKT1-SMUT/AKT1-SMUT
ratio, this fraction was clearly lower than the one observed in cells
expressing the WT protein (Figure 3b). These results suggested
that the SUMOylation of the AKT1 protein favored the activation
of the protein. In order to confirm this hypothesis, we co-
transfected MCF-7 cells with HA-AKT1-WT together with
pcDNA or Ubc9 and SUMO2. At 24 h after transfection, cells were
serum deprived for 24 h and then treated with insulin or
wortmannin. Then, activation of AKT as well as of some AKT
downstream targets was analyzed by western blot analysis. As
shown in Figure 3c, the p-AKT/AKT ratio in the untreated or
insuline-treated cells transfected with Ubc9 and SUMO2 was
higher than the one detected in cells transfected with pcDNA. In
agreement with these data, the phosphorylation of AKT substrates
FOXO and p70 was increased by cotransfection of Ubc9 and
SUMO2 (Figure 3c). These results indicated that SUMO induced
the activation of AKT, both at uninduced and insuline-induced
conditions.
We then decided to analyze the subcellular distribution of AKT
after SUMO transfection. HeLa cells were transfected with HA-AKT1-
WT in the presence or absence of Ubc9 and SUMO2 or with HA-
AKT1-SMUT, and 48 h after transfection, we performed a cell
fractionation assay. Western blot analysis using anti-HA antibody
revealed that transfected AKT1 was mainly detected in the
cytoplasm. In addition, we did not observe significant differences
in the localization of WT and SUMOylation mutant AKT1 protein
(Figure 3d and Supplementary Figure 3). However, transfection of
SUMO2 induced a decrease in HA-AKT1 protein levels in the
nucleus and the appearance of a band of the expected AKT-SUMO2
molecular weight in the cytoplasm (Figure 3d), indicating that the
AKT-SUMO2 protein is mainly localized in the cell cytoplasm.
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Modulation of AKT SUMOylation and its activation
To clarify the mechanism by which SUMO activates AKT, we
examined the putative phosphorylation of the AKT-SUMO protein
and its regulation. Western blot analysis of histidine-tagged
purified extracts obtained from HEK-293 cells co-transfected
with HA-AKT1-WT together with pcDNA or His6-SUMO2 and
Ubc9, revealed that a fraction of the conjugated AKT1-SUMO2
protein was phosphorylated (Figure 4a), indicating that
AKT1-SUMO protein can be activated. Similar experiments were
carried out using the constitutively active myristoylated
AKT1 construct (Myr-AKT1-WT). As shown in Figure 4b, SUMOyla-
tion of AKT1 was not affected by the AKT targeting to the cell
membrane. In addition, although the phosphorylation status of
unSUMOylated AKT clearly increased after the targeting to
the cell membrane, the levels of phosphorylated AKT-SUMO2
protein was not affected by myristoylation (Figure 4b). Then,
we analyzed the levels of phosphorylated AKT-SUMO2 protein
after modulation of the PI3K pathway. MCF-7 cells were co-
transfected with HA-AKT1-WT and pcDNA or Ubc9 and
His6-SUMO2, and 24 h after transfection, cells were serum starved
for 24 h and treated with insulin or wortmannin. Then,
histidine-tagged purified proteins were analyzed by western blot
analysis. As shown in Figure 4c, SUMOylation of AKT occurred
independently of the PI3K pathway and insuline treatment
did not result in the induction of AKT-SUMO2 protein phospho-
rylation. Furthermore, we observed the presence of phospho-
rylated AKT-SUMO2 in those cells treated with wortmannin even
when the levels of phosphorylated unSUMOylated AKT protein
were undetectable (Figure 4c), suggesting that activation of
AKT-SUMO protein occurs independently of the PI3K
pathway. Finally, we could not observe a regulation of AKT
SUMOylation after co-expression of the phosphatase PTEN
(Supplementary Figure 4). All together, these results indicated
that the SUMOylation of AKT is not dependent on the PI3K
pathway and it is not regulated by its targeting to the cell
membrane. In addition, these results also indicate that the
activation of the SUMOylated-AKT protein is independent of
PI3K activation.
We then wanted to analyze the putative interplay between AKT
SUMOylation and ubiquitination. Proteasome inhibition induces
the accumulation of mixed polyubiquitinated and polySUMOy-
lated chains of some substrates.13 Therefore, we decided to
evaluate whether AKT-SUMO2 chains accumulated in cells treated
with MG132. As shown in Figure 4d, AKT1-SUMO2 conjugation
was not affected by proteasome inhibition, suggesting that
SUMO2 conjugation does not work as a signal for polyubiquitina-
tion of AKT1.
Recently, it has been demonstrated that PML loss antagonizes
p-AKT inactivation, leading to AKT activation and function.14 The
results shown here indicate that SUMO also favors the activation
of AKT. We then decided to evaluate the effect of PML in the
SUMOylation of AKT. HEK-293 cells were co-transfected with HA-
AKT1-WT together with pcDNA or His6-SUMO2 and Ubc9, in the
presence or absence of pcDNA-PML, and western blot analysis of
the histidine-tagged purified proteins was carried out. The level of
AKT1-SUMO2 protein was clearly reduced in cells transfected with
PML (Figure 4e), indicating that PML negatively regulates the
SUMOylation of AKT.
Figure 2. Identification of the lysine residues in AKT1 that conjugate SUMO. (a) In vitro translated [35S]-labeled AKT1-WT or the indicated AKT1
mutants were subjected to in vitro SUMOylation assay in the presence of SUMO2. Proteins were resolved by SDS–polyacrylamide gel
electrophoresis (PAGE) and visualized by autoradiography. Quantification of AKT1-SUMO/AKT1 ratios is shown. (b) In vitro translated [35S]-
labeled AKT1-WT or an AKT1 mutated in three lysine residues, as indicated, were subjected to in vitro SUMOylation assay in the presence of
SUMO2. Proteins were resolved by SDS–PAGE and visualized by autoradiography. Quantification of AKT1-SUMO/AKT1 ratios is shown.
(c) Modification of transfected HA-AKT1-WT or HA-AKT1-SMUT by SUMO2 in HEK-293 cells. HEK-293 cells were co-transfected with HA-AKT1-
WT or HA-AKT1-SMUT together with pcDNA or Ubc9 and His6-SUMO2. Whole protein extracts or histidine-tagged purified proteins were
analyzed by western blot (WB) analysis using anti-HA antibody.
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SUMO contributes to the anti-apoptotic and pro-tumoral activity
of AKT
Activated AKT protein favors cell proliferation and inhibits the
apoptosis induced by different stimuli. As a first approach to test
the putative effect of SUMO on cell proliferation and AKT activation,
we decided to evaluate the consequences of Ubc9 down-
modulation on the proliferative rate and on the phosphorylation
status of AKT. Transfection of PC3 cells with siUbc9 significantly
reduced the proliferation rate of PC3 cells (Figure 5a, left panel) and
decreased the p-AKT/AKT ratio (Figure 5a, right panel). Furthermore,
incubation of the transfected cells with wortmannin for 24 h
abolished the proliferative advantage of the cells transfected with
small interfering RNA control (Figure 5a, left panel). These results
suggested a positive correlation between SUMOylation and AKT
activation. Then, in order to clearly determine the contribution of
SUMO to the proliferative and anti-apoptotic activity of AKT, we
generated a SUMOylation mutant of the constitutively active AKT1
protein and evaluated its SUMOylation in vivo. As shown in
Figure 5b, Myr-AKT1-WT protein was modified by SUMO2. However,
we did not detect SUMOylation of the Myr-AKT1-SMUT protein
(Figure 5b). In addition, we also observed that the p-AKT/AKT ratio
detected in the cells transfected with Myr-AKT1-WT was clearly
higher than the one detected in cells transfected with the mutant,
Myr-AKT1-SMUT, suggesting again that SUMO contributes to the
complete activation of AKT. Then, in order to evaluate the effect of
SUMOylation on the anti-apoptotic activity of AKT1, we generated
COS-7 cells that over-express Myr-AKT1-WT or Myr-AKT1-SMUT,
and 24 h after serum deprivation, we evaluated the phosphoryla-
tion of AKT and exposed the cells to ultraviolet irradiation as a
trigger of apoptosis.15 The levels of p-AKT observed in the COS-7
cells expressing Myr-AKT1-SMUT were lower than the ones
observed in the Myr-AKT1-WT-expressing cells (Figure 5c, left
panel). In addition, and as expected, Myr-AKT1-WT inhibited
ultraviolet-induced apoptosis in COS-7 cells (Figure 5c, right panel).
In contrast, expression of Myr-AKT1-SMUT was ineffective in
controlling ultraviolet-induced apoptosis (Figure 5c, right panel),
indicating that SUMOylation contributes to the anti-apoptotic
activity of AKT1.
Finally, in order to study the role of AKT1 SUMOylation in
oncogenesis, we generated NIH-3T3 cells that over-express Myr-
AKT1-WT or Myr-AKT1-SMUT, and 24 h after serum deprivation, we
performed a focus formation assay. Consistent with previously
published data showing that Myr-AKT1 can transform NIH-3T3
cells,16–18 the expression of Myr-AKT1-WT induced the formation
of foci in these cells, whereas the vector control cells failed to do
so (Figure 5d, left panel). The number of foci induced by Myr-
AKT1-SMUT was significantly lower than the one obtained in the
cells expressing the WT protein, in agreement with the lower pAKT
levels observed in the Myr-AKT1-SMUT-expressing cells (Figure 5d,
right panel). These results indicated that SUMOylation contributes
to the transforming activity of AKT1. All together, these data
indicated that SUMOylation contributes to the proliferative and
anti-apoptotic activity of AKT.
Figure 3. Activation of AKT by SUMO. (a) In vitro kinase assay using recombinant AKT1 protein subjected to in vitro SUMOylation assay in the
presence or absence of SUMO2 and recombinant p27 protein as a substrate. Phosphorylation of p27 was detected using anti-phospho-AKT
substrate antibody. Equal loading of p27 and AKT per reaction was confirmed by western blot (WB) analysis with the antibody directed
against p27 or AKT protein. (b) Protein extracts from MCF-7 cells transfected with HA-AKT-WT or HA-AKT-SMUT and subjected to starvation-
stimulation, as indicated, were subjected to immunoprecipitation with anti-HA antibody. Immunoprecipitated samples were run on a
SDS–polyacrylamide gel electrophoresis and analyzed by western blot analysis with the indicated antibodies. Numbers indicate
densitometrically determined p-AKT/AKT ratio. (c) Western blotting of lysates from MCF-7 cells co-transfected with HA-AKT1-WT and pcDNA
or Ubc9 and His6-SUMO2 and subjected to starvation-stimulation-inhibition. Numbers indicate densitometrically determined p-AKT/AKT or
pFOXO3a/FOXO3a ratios. (d) Fractionation of Hela cells transfected with the indicated plasmids. GAPDH and B23 were used as markers of the
cytoplasmic (C) and nuclear (N) fractions, respectively.
SUMOylation of AKT
CF de la Cruz-Herrera et al
1446
Oncogene (2015) 1442 – 1450 © 2015 Macmillan Publishers Limited
Figure 4. Modulation of AKT SUMOylation. (a) p-AKT in western blot (WB) analysis of AKT1-SUMO2. HEK-293 cells were co-transfected with
HA-AKT1 together with pcDNA or Ubc9 and His6-SUMO2. Histidine-tagged purified proteins were analyzed by western blot analysis using
anti-phospho-AKT (Ser-473) antibody or anti-HA antibody. (b) p-AKT in western blot analysis of Myr-AKT1-SUMO2 or AKT1-SUMO2. HEK-293
cells were co-transfected with Myr-AKT1 or HA-AKT1 and pcDNA or Ubc9 and His6-SUMO2. Whole protein extracts or histidine-tagged purified
proteins were analyzed by western blot analysis using anti-phospho-AKT antibody and the same membrane was reblotted with anti-AKT
antibody. (c) Western blot analysis of p-AKT-SUMO2 and AKT-SUMO2 in MCF-7 cells subjected to starvation-stimulation-inhibition. HEK-293
cells were co-transfected with HA-AKT1 together with pcDNA or Ubc9 and His6-SUMO2. After 24 h, cells were serum deprived for 16 h and
then mock treated, stimulated with insulin or treated with wortmannin. Whole protein extracts or histidine-tagged purified proteins were
analyzed by western blot analysis using anti-phospho-AKT or anti-HA antibodies. (d) Modification of AKT by SUMO2 after inhibition of the
proteasome. HEK-293 cells were co-transfected with HA-AKT1 and pcDNA or Ubc9 and His6-SUMO2. After 36 h, cells were treated or not with
MG132, as indicated. Whole protein extracts or histidine-tagged purified proteins were analyzed by western blot analysis using anti-AKT
antibody. (e) Modification of AKT by SUMO2 after overexpression of PML. HEK-293 cells were co-transfected with HA-AKT1 together with
pcDNA or Ubc9 and His6-SUMO2, and in the presence or absence of pcDNA-PML. Whole protein extracts or histidine-tagged purified proteins
were analyzed by western blot analysis using the indicated antibodies.
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DISCUSSION
The results reported here reveal that AKT interacts with Ubc9,
suggesting that AKT is a SUMO substrate. In agreement with this
possibility, we demonstrate that AKT1 can be SUMOylated by
SUMO1, SUMO2 and SUMO3 both in vitro and in vivo. However,
although SUMO2 or SUMO3 conjugation of AKT1 in vivo was
already detected in unstressed cells, AKT1-SUMO1 conjugation
in vivo was detected only after heat-shock conditions. These
results may indicate that AKT1 is not constitutively modified by
SUMO1 and instead is only modified by SUMO1 after cells are
exposed to stress conditions. However, a recent report on
Arabidopsis revealed that heat-shock stress mostly increases the
abundance of existing conjugates as opposed to modifying new
targets.12 Therefore, another possible explanation of the inability
to detect AKT1-SUMO1 in unstressed cells is that the small fraction
of AKT1 that is conjugated to SUMO1 at a specific time point
is too low to be detected. In agreement with this hypothesis,
we also observed an increase in the amount of AKT1-SUMO2 in
cells exposed to heat-shock stress. Interestingly, exposure of
Figure 5. SUMO favors AKT activity. (a) Growth rates of PC3 cells transfected with siUbc9 or siC were monitored by the MTT assay (left panel)
and starved-stimulated cells were analyzed by western blot (WB) analysis (right panel). In parallel, 48 h after transfection with siUbc9 or siC,
cells were treated with wortmannin (W) for 24 h when MTT incorporation was evaluated. Error bars are s.d. of quintuplicates. Numbers
indicate densitometrically determined p-AKT/AKT ratios. (b) Modification of transfected Myr-AKT1-WT or Myr-AKT1-SMUT by SUMO2 in
HEK-293 cells. HEK-293 cells were co-transfected with Myr-AKT1 or Myr-AKT1-SMUT and pcDNA or Ubc9 and His6-SUMO2. Whole protein
extracts or histidine-tagged purified proteins were analyzed by western blot analysis using the indicated antibodies. (c) Serum-starved COS-7
cells expressing Myr-AKT1 or Myr-AKT1-SMUT were analyzed by western blot analysis (left panel) and the percentage of apoptotic cells in
response to ultraviolet irradiation was then determined by flow cytometry (right panel). The results are presented as mean of three
independent experiments performed in triplicate, and error bars represent s.d. (d) Focus formation assay with NIH-3T3 cells expressing Myr-
AKT1 or Myr-AKT1-SMUT (left panel). Serum-starved cells were analyzed by western blot analysis (right panel). Error bars are standard
deviation (s.d.) of triplicates. *P<0.05, **P< 0.005, **P<0.0005, Student´s test.
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cells to heat shock has been reported to result in activation of
AKT,19,20 suggesting that SUMO may be implicated in this
activation.
By using in vitro and in vivo SUMOylation assays on AKT1
mutants, we demonstrate that lysine residue 64 at the PH domain,
which mediates lipid–protein and/or protein–protein interactions,
and the lysine residues 182 and 189 at the kinase domain work as
SUMO acceptors in AKT1. These three lysine residues are
evolutionary conserved between mouse and human, with 64
and 189 lysine residues being present in the three isozymes of
human AKT, and 182 in AKT1 and AKT3.
In vitro kinase assays using unmodified recombinant AKT1 or
in vitro SUMOylated recombinant AKT1 protein demonstrated that
SUMO increased the kinase activity of AKT1 in vitro. Similarly,
SUMO potentiated the activation and activity of AKT in transfected
cells. There are different mechanisms that may explain the
activation of AKT by SUMO. One possibility would be that the
interaction of SUMO with AKT strengthens its membrane
association. Alternatively, SUMO could hinder the deactivation of
AKT, as it has been proposed for the heat-shock protein 90.21
However, the higher kinase activity of the AKT1-SUMO protein
in vitro indicate the requirement of alternative explanations. The
constitutive disengage of the PH domain from the kinase domain
in AKT,22 and the dimerization of the protein23 have been
proposed as mechanisms that induce AKT phosphorylation. It is
well-known that SUMO attachment can induce a conformational
change in the substrate,24 that often has a positive effect on
protein–protein interactions, and that can promote the assembly
of several multi-protein complexes.25 It is therefore possible to
hypothesize that: the binding of SUMO to AKT may open the
conformation of the kinase, leading to the activation of the
protein; that SUMO may serve as a scaffold to recruit the adaptors
for AKT, in turn facilitating AKT activation; or that SUMO may
mediate the formation of homo- or hetero-multimeric protein
complexes, leading to the activation of AKT.
SUMOylation of many substrates is regulated through a
complex interplay with other post-translational modifications.
For example, phosphorylation can modulate SUMOylation26 and
SUMOylation with SUMO2 can promote ubiquitilation.27,28 We
could not detect a regulation of the AKT SUMOylation by
phosphorylation, and SUMO2 conjugation did not seem to act
as a signal for the polyubiquitilation of AKT1. However, we
identified PML as a negative modulator of AKT SUMOylation.
It is then tempting to speculate that the previously described
increased AKT activation associated with PML loss14 could be
related with the negative regulation of AKT SUMOylation by
PML.
Supporting a role for SUMO as an AKT activator, we detected a
decrease in cell proliferation and a reduction in the levels of
activated AKT upon down-modulation of the E2 SUMO-
conjugating enzyme Ubc9 in PC3 cells. Furthermore, a SUMOyla-
tion mutant of AKT showed reduced activation and compromised
proliferative and anti-apoptotic activities.
In summary, here we provide evidences that SUMO interacts
with and activates AKT. A deregulation of SUMO homeostasis has
been shown to be associated with different types of cancer, such
as prostate and breast cancer.29 It is therefore plausible that
SUMO may provide intrinsic survival signals in the absence of
external stimulation for AKT activation or that a deregulation of
the SUMO-AKT signaling pathway may underlie in human cancers.
Importantly, this post-translational modification of AKT may also
have consequences on therapeutic strategies as SUMO may
limit the efficacy of PI3K/AKT pathway inhibitors. However,
AKT-SUMO protein interaction may be an attractive target for
the design of new anticancer drugs. In this sense, the specific
targeting of the AKT-SUMO interaction may improve the
efficacy of PI3K/AKT inhibitors and reduce the side effects
resulting from inhibiting this pathway.
MATERIALS AND METHODS
Cell lines and plasmids
MCF-7, HEK-293, COS-7, HeLa, PC3 and NIH-3T3 cells were cultured in
complete medium (Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 1% penicillin). The cells were transiently trans-
fected using Xtreme (Roche, Farma SA, Madrid, Spain) or lipofectamine
(Invitrogen, Life Technologies SA, Madrid, Spain) transfection reagents, as
suggested by the manufacturer. After transfection, the cells were cultured
for 24 h in complete medium and then serum starved for 24 h before cell
stimulation, treatment with inhibitors or cell lysis. The vector encoding the
HA-tagged forms of Akt (HA-AKT1) and myristoilated Akt (Myr-AKT) were
previously described.30,31 A quick-change site-directed mutagenesis kit
(Stratagene, La Jolla, CA, USA) and the oligonucleotides listed in
Supplementary Table 1 were used to make single amino-acid changes
using HA-AKT1 or Myr-AKT plasmids as templates. His6-SUMO1, His6-
SUMO2, His6-SUMO3 and SV5-Ubc9 plasmids were previously described.32,33
Materials and antibodies
Wortmannin and insulin were purchased from Sigma (Madrid, Spain).
Smart-pool small interfering RNAs against Ubc9 (siUbc9) and scramble
small interfering RNA (siC) were purchased from Dharmacon (Thermo
Scientific, Epson, UK). AKT1 recombinant protein was purchased from
Calbiochem (Madrid, Spain). Recombinant p27 was expressed and purified
essentially as described.34 Antibodies to total AKT, phospho-FOXO1/3a
(Thr24/32), phospho-P70S6K (Thr-389), phospho-Ser-473 of AKT and
phospho-AKT substrate antibody were purchased from Cell Signaling
(Izasa SA, Barcelona, Spain). An anti-HA monoclonal antibody was
purchased from Covance (Madrid, Spain). Antibodies against PML,
FOXO3a and B23 were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-actin antibody was from MP Biomedicals (Illrich, France), anti-
tubulin antibody was from Serotec (Düsseldorf, Germany) and anti-GAPDH
was from Millipore (Madrid, Spain). Anti-SUMO2/3 antibody was from
Invitrogen.
In vitro SUMO conjugation assay
In vitro SUMO conjugation assays were performed on [35S]methionine-
labeled in vitro-transcribed/translated proteins as described previously.35
In vitro deSUMOylation assay
In vitro deSUMOylation assay with GST-SENP1 was performed on AKT1-
SUMO1 as described previously.7
Immunoprecipitation assay
Cells were lysed in RIPA buffer at 4 °C, centrifuged at 15 800× g for 5 min
and immunoprecipitated overnight at 4 °C after addition of 1 μl of the
specified antibody and 50 μl of 50% protein A-Sepharose CL-4B beads (GE
Healthcare, Madrid, Spain). Beads were then washed four times with RIPA
buffer and resuspended in 30 μl of SDS–polyacrylamide gel electrophoresis
(PAGE) loading buffer.
AKT in vitro kinase assay
Recombinant AKT1 protein was subjected to an in vitro SUMOylation assay
in the presence or absence of SUMO. Then the result of the SUMOylation
assay was employed in an in vitro kinase assay using p27 as a substrate.
The reaction was stopped by the addition of SDS–PAGE loading buffer, and
proteins were separated by SDS–PAGE and transferred to nitrocellulose
membrane. Phosphorylated p27 protein was evaluated using antibody
anti-p-AKT substrate. The blots were probed with anti-AKT and anti-p27 to
quantify protein levels.
Western blot analysis
Cells were washed in phosphate-buffered saline, scraped into SDS–PAGE
loading buffer and boiled for 5 min. Proteins of total extracts were
separated by SDS–PAGE and transferred onto a nitrocellulose membrane.
The membranes were incubated with the primary antibodies. Signals were
detected by using chemiluminescence. Quantification of band intensities
was performed by using ImageJ software and normalized to total protein
densitometry values.
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Purification of His-tagged conjugates
The purification of His-tagged conjugates using Ni2+-NTA- agarose beads,
allowing the purification of proteins that are covalently conjugated to
SUMO, was performed as described previously.36
Nucleo-cytoplasm separation
The nuclear and cytoplasmic factions were isolated using a nucleo-cytosol
fractionation kit (BioVision), according to manufacturer's protocol.
In vitro growth rate analysis
The in vitro growth rates of the cell lines were assessed by MTT pro-
liferation assay.
Focus formation assay
NIH-3T3 cells were co-transfected with pcDNA, Myr-AKT1-WT or Myr-AKT1-
SMUT and a puromycin resistance vector at a ratio 10:1. At 48 h after
transfection, cells were grown in medium supplemented with puromycin
antibiotic for 3 days. At this time, cells were plated in 60-mm dishes and
cultured in Dulbecco’s modified Eagle’s medium containing 5% fetal
bovine serum for 14 days, when colonies were visualized by crystal violet
staining.
Apoptosis quantification
Apoptosis was quantified by flow cytometry using the caspase-3, active
form, mAb Apoptosis kit from BD Pharmigen (BD Biosciences, Madrid,
Spain), according to manufacturer’s protocol.
Statistical analysis
For statistical analysis between control and different groups, the Student’s
t-test was applied. The significance level chosen for the statistical analysis
was Po0.05.
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